Expanding choices in intranasal steroid therapy: Summary of a roundtable meeting

Allergy and Asthma Proceedings

Volumn 27, Issue 3, 2006, Pages 254-264

  Blaiss, Michael S ^a,k   Benninger, Michael S ^b   Fromer, Len ^c   Gross, Gary ^d   Mabry, Richard ^e,f,g   Mahr, Todd ^h   Marple, Bradley ⁱ   Stoloff, Stuart ^j  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Prairie Medical Group   (United States)

^d Dallas Allergy & Asthma Center   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f Southwestern Medical Center   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^k NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

ARTICLE; CONSENSUS DEVELOPMENT; HAY FEVER; HUMAN; INTRANASAL DRUG ADMINISTRATION; NOSE; PATHOLOGY; PATIENT SATISFACTION; PERENNIAL RHINITIS; POWDER; SOLUTION AND SOLUBILITY;

ADMINISTRATION, INTRANASAL; GLUCOCORTICOIDS; HUMANS; NOSE; PATIENT SATISFACTION; PHARMACEUTICAL SOLUTIONS; POWDERS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 33746585786     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2006.27.2852     Document Type: Article

References (59)

1. Andersson M. Emerging treatments for allergic rhinitis. Expert Opin Emerg Drugs 8:63-69, 2003.
2. Bousquet J, Van Cauwenberge P, and Khaltaev N, and Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108(suppl): S147-S334, 2001.
3. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 111(suppl):S835-S842, 2003.
4. Dupclay L Jr, and Doyle J. Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences. Am J Manag Care 8(suppl):S335-S340, 2002.
5. Corren J. Allergic rhinitis and asthma: How important is the link? J Allergy Clin Immunol 99(suppl):S781-S786, 1997.
6. Leynaert B, Bousquet J, Neukirch C, et al. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects. J Allergy Clin Immunol 104:301-304, 1999.
7. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 99(suppl):S773-S780, 1997.
8. Benninger MS, Ahmad N, and Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg 129:739-750, 2003.
9. Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 161:2581-2587, 2001.
10. Trangsrud AJ, Whitaker AL, and Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 22:1458-1467, 2002.
11. Miller TR, Muntz HR, Gilbert ME, and Orlandi RR. Comparison of topical medication delivery systems after sinus surgery. Laryngoscope 114:201-204, 2004.
12. Naclerio RM. Allergic rhinitis. N Engl J Med 325:860-869, 1991.
13. Benninger MS, Hadley JA, Osguthorpe JD, et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg 130:5-24, 2004.
14. Saijo R, Majima Y, Hyo N, and Takano H. Particle deposition of therapeutic aerosols in the nose and paranasal sinuses after transnasal sinus surgery: A cast model study. Am J Rhinol 18:1-7, 2004.
15. GlaxoSmithKline. Beconase AQ prescribing information. Research Triangle Park, NC, 2002.
16. Ivax Laboratories. Nasarel prescribing information. Miami, FL, 2002.
17. AstraZeneca. Rhinocort Aqua prescribing information. Wilmington, DE, 2005.
18. Aventis Pharmaceuticals. Nasacort HFA prescribing information. Bridgewater, NJ, 2004.
19. Aventis Pharmaceuticals. Nasacort AQ prescribing information. Bridgewater, NJ, 2004.
20. GlaxoSmithKline. Flonase prescribing information. Research Triangle Park, NC, 2004.
21. Schering Corporation. Nasonex prescribing information. Kenilworth, NJ, 2005.
22. Newman SP, Pitcairn GR, and Dalby RN. Drug delivery to the nasal cavity: In vitro and in vivo assessment. Crit Rev Ther Drug Carrier Syst 21:21-66, 2004.
23. Homer JJ, Aggrawal R, and Cordoza A. Delivery of topical nasal drugs: Clinical implications for rhinosinusitis therapy research. Am J Drug Deliv 1:125-131, 2003.
24. Kippax PG, Krarup H, and Suman JD. Applications for droplet sizing: Manual versus automated actuation of nasal sprays. Pharm Technol 31-39, 2004.
25. Mygind N, and Vesterhauge S. Aerosol distribution in the nose. Rhinology 16:79-88, 1978.
26. Thorsson L, Borgå O, and Edsbäcker S. Systemic availability of budesonide after nasal administration of three different formulations: Pressurized aerosol, aqueous pump spray, and powder. Br J Clin Pharmacol 47:619-624, 1999.
27. Day J, Alexander M, Drouin M, et al. Budesonide aqueous nasal spray and pressurized metered dose inhaler in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 11:77-83, 1997.
28. Durand M, Rusch P, Granjon O, et al. Preliminary study of the deposition of aerosol in the maxillary sinuses using a plastinated model. J Aerosol Med 14:83-93, 2001.
29. 11C-labeled triamcinolone acetonide following intranasal administration in healthy volunteers. Clin Pharmacol Ther 55:183, 1994 (Abs PIII-4).
30. Berridge MS, Heald DL, Muswick GJ, et al. Biodistribution and kinetics of nasal carbon-11-triamcinolone acetonide. J Nucl Med 39:1972-1977, 1998.
31. Colthorpe P. Industry experiences of the HFA transition. Drug Delivery Systems and Sciences 3:41-43, 2003.
32. Gross G, Garcia J, Faruqi R, et al. Therapeutic equivalence of triamcinolone acetonide HFA and CFC nasal aerosols. Poster 267 presented at the program and abstracts of the American College of Allergy, Asthma, and Immunology, 2004 Annual Meeting, November 12-17, 2004, Boston, MA.
33. Weber R, Garcia J, Faruqi R, et al. Long-term safety and efficacy of a triamcinolone acetonide hydrofluroalkane-134A (HFA) nasal aerosol in patients with persistent allergic rhinitis. Poster P264 presented at the program and abstracts of the American College of Allergy, Asthma, and Immunology, 2004 Annual Meeting, November 12-17, 2004, Boston, MA.
34. Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalational aerosol), in asthma. J Allergy Clin Immunol 106:1209-1226, 2000.
35. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 87:405-411, 2001.
36. Lyttle B, Gilles J, Panov M, et al. Fluticasone propionate 100 microg bid using a non-CFC propellent, HFA 134a, in asthmatic children. Can Respir J 10:103-109, 2003.
37. Marple B, Roland P, and Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: An overview of conflicting data and opinions. Otolaryngol Head Neck Surg 130:131-141, 2004.
38. Khanvilkar K, Donovan MD, and Flanagan DR. Drug transfer through mucus. Adv Drug Deliv Rev 48:173-193, 2001.
39. Van de Donk HJM. Nasal medication and ciliary movement. Pharma Weekblad Sci Ed 5:32-33, 1983.
40. Marttin E, Schipper NGM, Verhoef JC, and Merkus FWHM. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Res 29:13-38, 1998.
41. 1 receptor antagonists in allergic rhinitis: Systematic review of randomized controlled trials. BMJ 317:1624-1629, 1998.
42. Adinoff A. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Pediatrics 110:441, 2002.
43. Corren J. Intranasal corticosteroids for allergic rhinitis: How do different agents compare? J Allergy Clin Immunol 104:S144-S149, 1999.
44. Benninger MS, and Marple BF. Minor recurrent epistaxis: Prevalence and a new method for management. Otolaryngol Head Neck Surg 131:317-320, 2004.
45. Ferguson BJ. Nasal steroid sprays and septal perforations. Ear Nose Throat J 76:75-76, 1997.
46. Derby L, and Maier WC. Risk of cataracts among users of intranasal corticosteroids. J Allergy Clin Immunol 105:912-916, 2000.
47. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105:e23, 2000.
48. Claxton AJ, Cramer J, and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310, 2001.
49. Loghman-Adham M. Medication noncompliance in patients with chronic disease: Issues in dialysis and renal transplantation. Am J Manag Care 9:155-171, 2003.
50. Gerson I, Green L, and Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications. J Sens Stud 14:491-496, 1999.
51. Richter A, Anton SE, Koch P, and Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 25:2307-2335, 2003.
52. Paes AH, Bakker A, and Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 20:1512-1517, 1997.
53. Andrejak M, Genes N, Vaur L, et al. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: Comparison of once daily versus twice daily regimens. Am J Hypertens 13:184-190, 2000.
54. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. Clin Ther 24:302-316, 2002.
55. Fromer LM. Clinical rationale for obtaining a precise diagnosis. J Fam Pract 53(suppl):S4-S14, 2004.
56. Kaliner MA. Patient preferences and satisfaction with prescribed nasal steroids for allergic rhinitis. Allergy Asthma Proc 22(suppl 1):S11-S15, 2001.
57. Meltzer EO, Hadley J, Blaiss M, et al. Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitis. Otolaryngol Head Neck Surg 132:197-207, 2005.
58. Bachert C, and El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 89:292-297, 2002.
59. Storms WW. Introduction: Patient preference of inhaled nasal corticosteroids. Allergy Asthma Proc 22(suppl 1):S1-S3, 2001.